IP Library Granted Patent US 8,283,447
Granted Patent B2
US 8,283,447 · App. 13/011,463 · Granted Oct 9, 2012

Immunosuppressive polypeptides and nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,283,447
App. No.
13/011,463
Granted
Oct 9, 2012
Kind
B2
Abstract

The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.

Claims (8)

1. An isolated or recombinant CTLA-4 polypeptide comprising a polypeptide sequence having at least 96% identity to the polypeptide sequence of SEQ ID NO:36.

2. The polypeptide of claim 1 , wherein the polypeptide comprises a polypeptide sequence that is 124 amino acid residues in length.

3. The polypeptide of claim 1 , wherein the CTLA-4 polypeptide comprises a polypeptide sequence having at least 97% identity to the polypeptide sequence of SEQ ID NO:36.

4. The polypeptide of claim 1 , wherein the CTLA-4 polypeptide comprises a polypeptide sequence having at least 98% identity to the polypeptide sequence of SEQ ID NO:36.

5. The polypeptide of claim 1 , wherein the CTLA-4 polypeptide comprises a polypeptide sequence having at least 99% identity to the polypeptide sequence of SEQ ID NO:36.

6. The polypeptide of claim 1 , wherein the CTLA-4 polypeptide comprises a polypeptide sequence having 100% identity to the polypeptide sequence of SEQ ID NO:36.

7. The polypeptide of claim 1 , wherein the CTLA-4 polypeptide comprises a phenylalanine at an amino acid position corresponding to position 70 of SEQ ID NO:36.

8. The polypeptide of claim 7 , wherein the CTLA-4 polypeptide further comprises an amino acid residue at a position relative to SEQ ID NO:36 selected from the group consisting of a glutamic acid residue at an amino acid position corresponding to position 24, an asparagine residue at an amino acid position corresponding to position 30, an isoleucine residue at an amino acid position corresponding to position 32, a methionine residue at an amino acid position corresponding to position 50, a lysine residue at an amino acid position corresponding to position 54, a glutamic acid residue at an amino acid position corresponding to position 55, an aspartic acid residue at an amino acid position corresponding to position 56, a proline residue at an amino acid position corresponding to position 64, a serine residue at an amino acid position corresponding to position 65, and a glutamic acid residue at an amino acid position corresponding to position 104.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2013
From: PERSEID THERAPEUTICS LLC
To: ASTELLAS PHARMA INC.
Reel/Frame 031391/0909 →